Acorda Therapeutics Announces Company Intranet Named One of Ten Best in the World

  Acorda Therapeutics Announces Company Intranet Named One of Ten Best in the
  World

Business Wire

ARDSLEY, N.Y. -- February 14, 2013

Acorda Therapeutics, Inc. (Nasdaq: ACOR) and partner Klick Health today
announced that Acorda’s intranet site has been named as one of the ten best in
the world by the Nielsen Norman Group, leading experts in web usability, which
annually recognizes the global top 10 intranet sites for innovation and
usability.

Acorda’s intranet was launched in late 2011. Prior to designing the site, the
internal development team and Klick Health conducted interviews throughout the
company to determine what types of functionality and features would best allow
employees to access and share information, improve efficiency across the
organization, and help Acorda’s associates stay connected to the Company’s
mission and to one another.

The site launch was preceded by a company-wide contest to name the new
intranet. The Acorda intranet development team selected “Synapse,” a
specialized structure in the brain necessary for nerve conduction and
communication, to tie the site’s purpose and name back to Acorda’s mission to
develop therapies for people with neurological diseases.

“We’ve expanded rapidly over the past five years. We needed to develop a tool
that would help our associates remain connected to the Company’s culture and
values, and keep pace with the growing business needs of our organization,"
said Ron Cohen, M.D., Acorda’s president and CEO. “We invested a lot of time,
together with Klick, in learning how our employees wanted to use an intranet.
Synapse now houses easily accessible information ranging from human resources
forms to R&D updates; it’s also a living site with social features that allow
employees to communicate with company-wide updates and messages. And we’re
excited about the potential for new applications of Synapse as we continue to
grow.”

Klick Health has been working with Acorda since 2009 on a variety of online
initiatives.

“Through our partnership with Acorda we’ve been able to accomplish some
amazing things this year, earning a place atop the coveted Nielsen Norman
Group global top 10 intranet list being chief among them,” said Leerom Segal,
president and CEO of Klick Health. “With similar cultures, growth rates, and
company size, we were a natural partner to develop this tool to truly address
Acorda’s needs. Building off the success of our own intranet system, Genome,
we were able to work with Acorda to provide its employees with a great
opportunity to preserve their culture while optimizing the way they get things
done.”

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company focused on developing therapies
that restore function and improve the lives of people with MS, spinal cord
injury and other neurological conditions.

Acorda markets AMPYRA^® (dalfampridine) Extended Release Tablets, 10 mg, in
the United States as a treatment to improve walking in patients with multiple
sclerosis (MS). This was demonstrated by an improvement in walking speed.
AMPYRA is marketed outside the United States as FAMPYRA^® (prolonged-release
fampridine tablets) by Biogen Idec under a licensing agreement from Acorda.
AMPYRA and FAMPYRA are manufactured under license from Alkermes Pharma Ireland
Limited.

The Company also markets ZANAFLEX CAPSULES^® (tizanidine hydrochloride) and
Zanaflex tablets, a short-acting drug for the management of spasticity. Acorda
also receives sales royalties on tizanidine hydrochloride capsules, an
authorized generic version of ZANAFLEX CAPSULES, distributed by Actavis, Inc.
under its agreement with Acorda.

Acorda has an industry-leading pipeline of novel neurological therapies. The
Company is developing Diazepam Nasal Spray for treatment of certain epileptic
seizures. It is also studying AMPYRA to improve a range of functional
impairments caused by MS, as well as its potential for use in other
neurological conditions, including cerebral palsy and post-stroke deficits. In
addition, Acorda is developing clinical stage compounds AC105 for acute
treatment of spinal cord injury, GGF2 for treatment of heart failure and
rHIgM22, a remyelinating monoclonal antibody, for the treatment of MS.GGF2 is
also being investigated in preclinical studies as a treatment for neurological
conditions such as stroke and spinal cord injury. Chondroitinase, an enzyme
that encourages nerve plasticity in spinal cord injury, is in preclinical
development.

About Klick

Klick Health is the world’s largest independent digital health agency. They
are laser focused on creating digital solutions that engage and educate
healthcare providers about life-saving treatments. Klick also helps inform and
empower patients to manage their health and play a central role in their own
care. Every solution hinges on Klick’s in-house expertise across the digital
universe – strategy, creative, analytics, instructional design, user
experience, relationship marketing, social and mobile.

www.klick.com

About Nielsen Norman Group

Nielsen Norman Group (http://www.nngroup.com) in an evidence-based user
experience research, training and consulting firm that advises companies on
how to improve the bottom line through human-centered design of products and
services. NN/g principals Jakob Nielsen, Don Norman and Bruce "Tog" Tognazzini
are each world-renowned user experience experts who were advocating
human-centered design and usability long before it became popular to do so.
Founded in 1998 and headquartered in Silicon Valley, NN/g evaluates interfaces
of all kinds and guides the critical design decisions that make websites,
applications, intranets and products achieve their full potential for
businesses and their users.

Acorda Forward-Looking Statements

This press release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All statements, other
than statements of historical facts, regarding management's expectations,
beliefs, goals, plans or prospects should be considered forward-looking. These
statements are subject to risks and uncertainties that could cause actual
results to differ materially, including our ability to successfully market and
sell Ampyra in the U.S.; third party payers (including governmental agencies)
may not reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results from future
studies of Ampyra or from our other research and development programs,
including Diazepam Nasal Spray or any other acquired or in-licensed programs;
we may not be able to complete development of, obtain regulatory approval for,
or successfully market Diazepam Nasal Spray or other products under
development; the occurrence of adverse safety events with our products; delays
in obtaining or failure to obtain regulatory approval of or to successfully
market Fampyra outside of the U.S. and our dependence on our collaboration
partnerBiogen Idecin connection therewith; competition, including the impact
of generic competition on Zanaflex Capsules revenues; failure to protect our
intellectual property, to defend against the intellectual property claims of
others or to obtain third party intellectual property licenses needed for the
commercialization of our products; failure to comply with regulatory
requirements could result in adverse action by regulatory agencies; and the
ability to obtain additional financing to support our operations. These and
other risks are described in greater detail inAcorda Therapeutics'filings
with the Securities & Exchange Commission.Acordamay not actually achieve the
goals or plans described in its forward-looking statements, and investors
should not place undue reliance on these statements. Forward-looking
statements made in this release are made only as of the date hereof, and
Acorda disclaims any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of this
release.

Contact:

Acorda Therapeutics
Jeff Macdonald, 914-326-5232
jmacdonald@acorda.com
or
Klick Health
Peter Flaschner, 416-214-4977 ext. 2408
pr@klick.com
 
Press spacebar to pause and continue. Press esc to stop.